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DOI 10.1186/s12891-015-0580-8RESEARCH ARTICLE Open AccessTamoxifen use reduces the risk of osteoporotic
fractures in women with breast cancer in Asia: a
nationwide population-based cohort study
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Purpose: Bone mineral density changes with tamoxifen treatment have been reported in pre- and post-menopausal
women with breast cancer. However, there remains controversy as to whether tamoxifen significantly reduces fracture
rates in different age groups. Breast cancer occurs at 10-20 years younger in Asian women compared with Western
women. Therefore we conducted this population-based case-control study to determine whether or not tamoxifen use
is associated with osteoporotic fractures.
Patients and methods: We selected 75488 women with breast cancer with no prior history of fractures from the
Longitudinal Health Insurance Database for Catastrophic Illness Patients in 2000-2011. They were followed from the
date of the diagnosis of breast cancer to the date a hip, vertebral or wrist fracture occurred. Because the use of
tamoxifen was a time-dependent variable, we used a Cox proportional hazard model with time-dependent exposure
covariates to estimate the risk of a fracture.
Results: There were 50257 and 25231 women with breast cancer who did and did not receive tamoxifen treatment,
respectively. The tamoxifen users had lower risks for overall fractures with hazard ratios (HRs) of 0.52 and 0.59 in the
crude and adjusted models (95 % CI = 0.45-0.61 and 0.51-0.69), respectively. They also had lower risks for hip (HR = 0.55,
95 % CI = 0.45-0.67) and vertebral (HR = 0.64, 95 % CI = 0.50-0.82) fractures in the adjusted model. The risk of fractures
decreased with an increasing dosage of tamoxifen. Regardless of the age group, the tamoxifen users had a lower risk of
fractures than the non-users.
Conclusion: In this Asian population-based case-control study, tamoxifen use was associated with a reduction in
osteoporotic fractures, especially in hip fractures.
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Breast cancer survivors have an increased risk of osteo-
porosis and fractures [1, 2]. This elevated risk of frac-
ture could be due to the effects of chemotherapy,
ovarian failure, early menopause, and the use of
aromatize inhibitors (AI) [3–5]. Although the peak in
the age of breast cancer among Asian women occurs
much earlier than in Western women (40-50 years vs.
60-70 years) [6], we previously showed that Asian breast* Correspondence: ritsai8615@gmail.com
1Graduate Institute of Clinical Medicine, China Medical University, #91
Hsueh-Shih Road, Taichung 404, Taiwan
3School of Medicine, China Medical University, Taichung, Taiwan
Full list of author information is available at the end of the article
© 2015 Tzeng et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cancer survivors have a higher risk of fractures, particu-
larly those below the age of 50 [7].
Tamoxifen has been used since the 1990s as an adjuvant
treatment for breast cancer patients who are estrogen re-
ceptor (ER)-positive. Tamoxifen has estrogen-like effects
on bone metabolism that may result in an increase and
stabilization of BMD. However, the effectiveness of this
bone protection between pre- and post-menopausal
women remains debatable. A significant loss of BMD in
pre-menopausal women receiving Tamoxifen treatment
has been reported, whereas it has been shown to prevent
bone loss in post-menopausal women [8]. In addition, the
proactive effect in terms of fractures related to tamoxifen
is also controversial in clinical practice. Kristensen et al.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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against fractures in old age and may even increase the risk
of fractures at particular sites [9]. On the other hand, a
large population-based study in Canada revealed a pro-
tective effect of concurrent tamoxifen treatment against
overall osteoporotic fractures, especially hip fractures [10].
Whether or not tamoxifen offers a protective effect
with regards to the risk of fractures in Asian women
with breast cancer should ideally be investigated among
those whose major peak age is 10 years younger than in
Western women with breast cancer. Therefore, we used
National Health Insurance (NHI) claims data in Taiwan
to assess this relationship.
Methods
We used the Longitudinal Health Insurance Database
for Catastrophic Illness Patients (LHID-CIP), a part of
the National Health Insurance Research Database
(NHIRD), from the National Health Research Institutes
(NHRI) for this retrospective cohort study. The Taiwan
Bureau of National Health Insurance (TBNHI) estab-
lished a universal NHI Program in 1995, which currently
covers over 99 % of the population in Taiwan. The
TBNHI entrusted the NHRI to construct and maintain
the NHIRD for research purposes. The NHIRD includes
all inpatient and outpatient claims for each beneficiary
from 1997 to 2011. The LHID-CIP includes all patients
conforming to the guidelines of the TBNHI for a cata-
strophic illness certificate. Patients with a catastrophic
illness certificate are exempt from copayment for med-
ical care, and this certificate is formally reviewed by a
physician upon application. Diseases are, identified in
the NHIRD based on International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes. Based on the Personal Information Protection
Act, the identification of beneficiary is scrambled by
the TBNHI, and all researchers are required to sign a
written agreement regarding their intentions when
attempting to obtain the private data of patients when
the NHIRD is released. This study was also approved
by the Institutional Review Board of China Medical
University Hospital.
We collected data on women with a diagnosis of
breast cancer (ICD-9-CM 174) from 2000 to 2011 from
the LHID-CIP as the study population, and the date of
diagnosis was used as the index date. However ,the data
dose not record the stage of breast cancer. Those that
received tamoxifen [Anatomical Therapeutic Chemical
code (ATC code) L02BA01] before the index date or
those with a prior history of fractures (ICD-9-CM 800-
829) within 1 year before the index date were excluded.
All of the included breast cancer patients were followed
from the index date until the date a hip (ICD-9-CM
820), vertebral (ICD-9-CM 805) or wrist (ICD-9-CM815) fracture occurred. Those without a fracture were
followed to the date of withdrawal from the NHI program
or to the end of 2011.
The exposure was defined the breast cancer women
received Tamoxifen during the study period. According
to the World Health Organization defined the assumed
average maintenance dose per day for a drug used for its
main indication in adults, defined daily doses (DDD) is
a statistical measure of drug consumption. (WHO Collab-
orating Centre for Drug Statics Methodology. Available
from: http://www.whocc.no/use_of_atc_ddd/#Pharmaceutical).
The accumulated Tamoxifen DDDs during the study period
was calculated for each user.
The comorbidities considered were hypertension (ICD-
9-CM 401-405), hyperlipidemia (ICD-9-CM 272), diabetes
(ICD-9-CM 250), peripheral artery disease (PAD, ICD-9-
CM 440.0, 440.2, 440.3, 440.8, 440.9, 443, 444.0, 444.22,
444.8, 447.8 and 447.9), stroke (ICD-9-CM 430-438)
and osteoporosis (ICD-9-CM 733.0 and 733.1). All comor-
bidities were defined before the index date. The medical
treatments considered were hormone replacement
therapy (HRT, ATC codes G03AA08, G03AC06, G03CA57,
G03DA02, G03DA03, G03DA04, G03FA01, G03FA02,
G03FA12, G03FB01, G03FB06 and L02AB02) and aroma-
tase inhibitors (AIs, ATC code L02BG). HRT users were
defined as those who received treatment before the index
date. Because AIs are used to treat women with breast
cancer, AI users were defined as those who received
treatment before the fracture occurred.
The chi-square test was used to test differences be-
tween age groups (<50, 50-59, 60-69 and ≥70 years),
and comorbidities between the women with breast can-
cer who did and did not receive tamoxifen treatment.
Because the breast cancer patients may not always have
received tamoxifen and AIs during the study period
and this may have overestimated the effect of the drugs,
we used a Cox proportional hazard model with time-
dependent exposure covariates to estimate the risk of
fractures in order to reduce this bias. The multivariate
Cox proportional hazard model with time-dependent
covariates was adjusted for age, monthly income, co-
morbidities and medicine used, and significant differ-
ences were found (Table 1). The effects of dose on
fractures were estimated according to the dosage or
duration of tamoxifen treatment. The association be-
tween different locations of fractures and tamoxifen
use was then assessed. The age-specific risk and each
comorbidity-specific risk for different locations of
fractures among those who did and did not receive
tamoxifen were also estimated. All statistical analyses
were performed using SAS software version 9.3 (SAS
Institute Inc., Carey, NC), and a two-tailed p value of
less than 0.05 was considered to indicate statistical
significance.
Table 1 Demographic characteristics of the study subjects
All N = 75488 With tamoxifen N = 50257 Without tamoxifen N = 25231
Variable n % n % n % p-value
Age, years <0.0001
<50 35715 47.3 25778 51.3 9937 39.4
50-59 21676 28.7 13124 26.1 8552 33.9
60-69 11353 15.0 7001 13.9 4352 17.6
70+ 6744 8.93 4354 8.66 2390 9.47
Urbanization 0.34
Urban 50793 67.3 33874 67.4 16919 67.1
Rural 24695 32.7 16383 32.6 8312 32.9
Month income, NTD <0.0001
<= 15000 12795 17.0 8231 16.4 4564 18.1
15001-20000 39463 52.3 26326 52.4 13137 52.1
>20000 33230 30.8 15700 31.2 7530 29.8
Comorbidity
Hypertension 21882 29.0 14142 28.1 7740 30.7 <0.0001
Hyperlipidemia 15458 20.5 9952 19.8 5506 21.8 <0.0001
Diabetes 8948 11.9 5698 11.3 3250 12.9 <0.0001
PAD 1477 1.96 905 1.80 572 2.27 <0.0001
Stroke 1715 2.27 1012 2.01 703 2.79 <0.0001
Osteoporosis 8024 10.6 5114 10.2 2910 11.5 <0.0001
Medicine, n (%)
HRT used before the index date 36690 48.6 24487 48.7 12203 48.4 0.35
Aromatase inhibitors used before the end point 20507 27.2 16273 32.4 4234 16.8 <0.0001
Chi-square test
PAD, peripheral artery disease
Tzeng et al. BMC Musculoskeletal Disorders  (2015) 16:123 Page 3 of 7Results
We collected data on 75,488 women with breast cancer,
of whom 50,257 and 25,231 did and did not receive
tamoxifen treatment, respectively. Compared with the
patients who did not receive tamoxifen treatment, the
tamoxifen users were younger (mean age 51.7 vs.
53.5 years, data not shown) and had fewer comorbidi-
ties (Table 1). There was no significant difference in the
urbanization of residential area between the tamoxifen
users and non-users, however the tamoxifen users had
a higher income than the non-users.
According to the Cox proportional hazard model
with time-dependent covariates, the tamoxifen users
had lower risks of fractures with hazard ratios (HRs)
of 0.52 and 0.59 in the crude and adjusted models
(95 % CI = 0.45-0.61 and 0.51-0.69), respectively
(Table 2). The same trends for hip, vertebral and wrist
fractures were also noted, however only wrist fractures
were found to not be significantly different. The risk
of fractures significantly decreased with the dosage
and duration of tamoxifen use for both overall and hip
fractures.The associations between fractures and potential risk
factors are presented in Table 3. In the multivariate Cox
proportional hazard model with time-dependent covari-
ates, the risk of fractures increased with age. Compared
with the patients who had a higher monthly income
(>20000 NTD), those with a lower monthly income had
a higher risk of fractures. The patients with diabetes had
the highest risk (HR = 1.59, 95 % CI = 1.37-1.85),
followed by stroke, osteoporosis and hypertension. How-
ever, the patients with hyperlipidemia and AI treatment
had a significantly lower risk of fractures (HR = 0.83 and
0.80, 95 % CI = 0.72-0.96 and 0.68-0.95, respectively).
Table 4 shows the age-specific risk of fractures among
those who did and did not receive tamoxifen treatment.
In each age group, the risks of overall and hip fractures
were lower in the tamoxifen users than in the non-users.
For vertebral fractures, only the tamoxifen users who
were 70 years and older had a significantly lower risk of
fractures. Comorbidity-stratified analysis is shown in
Table 5. Regardless of the comorbidities, the tamoxifen
users tended to have a lower risk of fractures than the
non-users.
Table 2 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for different locations of fractures in the time-dependent model
Location Crude HR (95 % CI) p-value Adjusted HR (95 % CI) p-value
Overall
Tamoxifen use (yes vs. no) 0.52 (0.45-0.61) <0.0001 0.59 (0.51-0.69) <0.00001
Increased dose of tamoxifen, per 100 DDD 0.98 (0.97-0.99) 0.0003 0.98 (0.97-0.99) 0.0002
Increased duration of tamoxifen use, per 100 days 0.98 (0.97-0.99) 0.0004 0.98 (0.97-0.99) 0.0002
Hip fracture
Tamoxifen use (yes vs. no) 0.48 (0.39-0.57) <0.0001 0.55 (0.45-0.67) <0.0001
Increased dose of tamoxifen, per 100 DDD 0.97 (0.96-0.99) 0.0003 0.97 (0.96-0.99) 0.0005
Increased duration of tamoxifen use, per 100 days 0.98 (0.96-0.99) 0.001 0.97 (0.96-0.99) 0.0004
Vertebral fracture
Tamoxifen use (yes vs. no) 0.59 (0.46-0.75) <0.0001 0.64 (0.50-0.82) 0.0003
Increased dose of tamoxifen, per 100 DDD 0.98 (0.97-1.00) 0.15 0.98 (0.97-1.00) 0.06
Increased duration of tamoxifen use, per 100 days 0.98 (0.97-1.00) 0.09 0.98 (0.97-1.00) 0.06
Wrist fracture
Tamoxifen use (yes vs. no) 0.86 (0.43-1.71) 0.66 0.84 (0.42-1.68) 0.62
Increases dose of tamoxifen, per 100 DDD 1.01 (0.96-1.06) 0.83 1.01 (0.96-1.06) 0.76
Increased duration of tamoxifen use, per 100 days 1.01 (0.96-1.05) 0.83 1.01 (0.96-1.05) 0.86
Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aromatase inhibitor use before the end point
DDD, defined daily dose
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Tamoxifen, a non-genomic ER ß agonist but selective
antagonist of ER α, has been shown to have a beneficial
effect on bone metabolism [11]. Tamoxifen may increase
BMD in the lumbar spine and especially in post-
menopausal women with breast cancer. However, little is
known regarding its effect on fractures, and the results
of previously published studies remain controversial in
clinical practice. Cooke et al reported that current use of
tamoxifen led to a significantly lower overall risk ofTable 3 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for f
Variable Crude HR (95 % CI)
Age, years 1.10 (1.10-1.1
Monthly income, NTD
<= 15000 4.85 (3.98-5.9
15001-20000 2.25 (1.86-2.7
>20000 1.00 Ref.







Aromatase inhibitor use before the end point 1.18 (1.00-1.4
Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aroma
PAD, peripheral artery diseaseosteoporotic fractures in a population-based case-control
study [10]. However, a number of reports in the literature
have reported no statistically significant bone protection at
an age of 65 years and older [12, 13].
In comparison with previous population-based fracture
risk studies, of which most have included post-menopausal
woman, approximately 50 % of the cases were under
50 years of age in our study. Our results parallel another
study in terms of the protective site of tamoxifen use.
Tamoxifen has been shown to preserve BMD in theractures and potential risk factors in the time-dependent model
p-value Adjusted HR (95 % CI) p-value
1) <0.0001 1.09 (1.08-1.10) <0.0001
1) <0.0001 1.34 (1.08-1.66) 0.009
1) <0.0001 1.51 (1.25-1.82) <0.0001
1.00 Ref.
9) <0.0001 1.27 (1.09-1.48) 0.002
0) <0.0001 0.83 (0.72-0.96) 0.01
9) <0.0001 1.59 (1.37-1.85) <0.0001
4) <0.0001 0.99 (0.72-1.36) 0.96
3) <0.0001 1.38 (1.08-1.76) 0.01
8) <0.0001 1.38 (1.19-1.59) <0.0001
0) 0.049 0.80 (0.68-0.95) 0.01
tase inhibitor use before the end point
Table 4 Adjusted hazard ratios (HRs) and 95 % confidence
intervals (CIs) for different fracture locations in the time-dependent
model among age group
Age group Tamoxifen user vs.
non-user HR (95 % CI)
p-value Interaction p
Overall 0.29
<50 0.54 (0.36-0.82) 0.004
50-59 0.58 (0.40-0.83) 0.003
60-69 0.66 (0.50-0.88) 0.005
70+ 0.59 (0.48-0.74) <0.0001
Hip fracture 0.046
<50 0.39 (0.19-0.81) 0.01
50-59 0.38 (0.20-0.72) 0.003
60-69 0.56 (0.38-0.81) 0.002
70+ 0.61 (0.47-0.78) 0.0001
Vertebral fracture 0.86
<50 0.59 (0.34-1.03) 0.06
50-59 0.74 (0.46-1.19) 0.21
60-69 0.84 (0.54-1.32) 0.46
70+ 0.54 (0.34-0.85) 0.008
Wrist fracture 0.26
<50 0.90 (0.31-2.57) 0.84
50-59 0.76 (0.25-2.34) 0.63
60-69 1.44 (0.20-10.6) 0.72
70+ 1.10 (0.07-17.9) 0.94
Manually adjusted for monthly income, comorbidity and aromatase inhibitor
use before the end point
Table 5 Hazard ratio (HRs) and 95 % confidence intervals (CIs)
for fractures in the tamoxifen users compared with non-users
using the time-dependent model stratified by comorbidity
Comorbidity Tamoxifen user vs.
non-user HR (95 % CI)
p-value Interaction p
Hypertension 0.18
No 0.67 (0.53-0.85) 0.001
Yes 0.55 (0.46-0.66) <0.0001
Hyperlipidemia 0.97
No 0.60 (0.50-0.72) <0.0001
Yes 0.58 (0.45-0.74) <0.0001
Diabetes 0.56
No 0.62 (0.52-0.74) <0.0001
Yes 0.54 (0.41-0.71) <0.0001
PAD 0.58
No 0.59 (0.50-0.68) <0.0001
Yes 0.73 (0.37-1.46) 0.38
Stroke 0.32
No 0.59 (0.50-0.69) <0.0001
Yes 0.68 (0.41-1.13) 0.14
Osteoporosis 0.33
No 0.61 (0.51-0.73) <0.0001
Yes 0.54 (0.40-0.72) <0.0001
PAD, peripheral artery disease
Manually adjusted for monthly income, comorbidity and aromatase inhibitor
use before the end point
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bone loss in the hip and spine but not the wrist in
post-menopausal woman [14–17]. The preservation of
BMD by tamoxifen in post-menopausal women is asso-
ciated with a reduced risk of osteoporotic fractures.
Despite these findings, several studies have demon-
strated that tamoxifen accelerates bone loss in pre-
menopausal women. The results of the current study in-
dicate that, after adjustment for potential confounding
factors, patients receiving tamoxifen are at a lower risk
of developing osteoporotic fractures overall, including
spine and hip fractures, compared with those not receiv-
ing tamoxifen. The protective effect was also related to
age, and especially those under 50 years of age. A lower
risk of fractures was seen in both the older and younger
patients. Another population-based study suggested that
the protective effect of prior tamoxifen use was quickly
lost after the treatment was changed to letrozole [10].
We did not compare the effect of other AIs with tamoxi-
fen. Our results revealed that the protective effect was not
related to the duration or dosage, so it may have been due
to the steady usage of tamoxifen once a patient had been
prescribed with this drug. There is a debate regarding theuse of AIs and tamoxifen for the treatment of women with
ER-positive breast cancer. The risk of relapse has been re-
ported to persist after 5 years of treatment with adjuvant
tamoxifen in post-menopausal women with hormone-
sensitive early stage breast cancer [16]. Published cost-
effectiveness analyses comparing AIs to tamoxifen have
assumed an overall survival and indicated a higher risk
of fractures with AIs, although this has not been shown
in RCTs, leading to an overestimation of the cost-
effectiveness of AIs [18]. If anastrozole use is associated
with an increased risk of hip fractures, then the long-term
benefits associated with this agent are reduced by approxi-
mately 25 % [19]. Less than half of hip fracture patients re-
sume baseline levels of functioning, and nearly one in five
requires long-term nursing home care after a hip fracture
[20]. Concerns regarding the use of tamoxifen include
menopausal symptoms, deep vein thrombosis, and
endometrial cancer [21]. It has also been reported to
increase the risk of abnormal endometrial thickness in
post-menopausal women, although this has not been
proven in pre-menopausal Asian women with breast can-
cer [22]. In addition, a recent study reported no increased
risk of venous thromboembolism in Asian breast cancer
patients receiving adjuvant tamoxifen treatment [23].
Tzeng et al. BMC Musculoskeletal Disorders  (2015) 16:123 Page 6 of 7The strength of our study is the use of a population-
based data set with the enrollment of a large number of
patients. However, several limitations must be consid-
ered when interpreting these findings. The insurance
claims files do not provide information on serum estro-
gen level, BMD, cancer stage or menopausal status. We
were therefore unable to determine whether patients
with advanced stages of the cancer or post-menopause
were at a greater risk of fractures. Serum estrogen has
been reported to be a risk factor for breast cancer, and a
higher exposure to estrogen has been reported to pre-
serve BMD and thereby decrease the risk of osteoporotic
fractures [24–27]. A correlation between a higher BMD
and a higher risk of breast cancer has been reported
[28]. Therefore, the reduced risk of osteoporotic frac-
tures in tamoxifen users may be due to prior exposure
to endogenous estrogen [10].
Physicians need to weigh the benefits and risks of tam-
oxifen treatment in various clinical situations. In our
opinion, the protective effect of tamoxifen is advised for
younger patients, especially in Asian patients who have a
higher risk of fractures at a younger age.
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